We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-12.71%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.09B
AUM Growth
+$188M
Cap. Flow
+$375M
Cap. Flow %
34.46%
Top 10 Hldgs %
59.52%
Holding
48
New
18
Increased
11
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$52M
2
PEN icon
Penumbra
PEN
+$46.4M
3
UTHR icon
United Therapeutics
UTHR
+$37.9M
4
ZYME icon
Zymeworks
ZYME
+$35.1M
5
DXCM icon
DexCom
DXCM
+$23.5M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$28M
2
ASND icon
Ascendis Pharma A/S
ASND
+$22.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$15.3M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$5.02M
5
RVLP
RVL Pharmaceuticals plc Ordinary Shares
RVLP
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 85.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$1.82B
$95.7M 8.8%
5,260,803
– –
ZGNX
2
DELISTED
Zogenix, Inc.
ZGNX
$80.1M 7.36%
2,000,000
+406,604
+26% +$18.7M
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.43B
$78.8M 7.24%
2,190,742
+690,742
+46% +$20.9M
BOLD
4
DELISTED
Audentes Therapeutics, Inc
BOLD
$69.8M 6.41%
2,485,000
+562,063
+29% +$19.2M
PTCT icon
5
PTC Therapeutics
PTCT
$5.64B
$67.6M 6.21%
2,000,000
+25,615
+1% +$1.11M
ZYME icon
6
Zymeworks
ZYME
$1.61B
$61.2M 5.62%
2,466,744
+1,402,703
+132% +$35.1M
XLRN
7
DELISTED
Acceleron Pharma
XLRN
$57.5M 5.28%
1,454,700
+5,400
+0.4% +$234K
MDCO
8
CALL
DELISTED
Medicines Co
MDCO
$50M 4.59%
+1,000,000
New +$39.9M
KURA icon
9
Kura Oncology
KURA
$800M
$46.8M 4.3%
3,086,053
+38,253
+1% +$681K
PEN icon
10
Penumbra
PEN
$12.6B
$40.3M 3.71%
+300,000
New +$46.4M
NKTR icon
11
Nektar Therapeutics
NKTR
$2.39B
$38.7M 3.56%
+141,667
New +$52M
ASND icon
12
CALL
Ascendis Pharma A/S
ASND
$16B
$38.5M 3.54%
+400,000
New +$44.6M
UTHR icon
13
United Therapeutics
UTHR
$25.8B
$37.5M 3.44%
+470,000
New +$37.9M
ASND icon
14
Ascendis Pharma A/S
ASND
$16B
$28.9M 2.65%
300,000
-200,000
-40% -$22.3M
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$23.4M 2.15%
300,000
– –
MRTX
16
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$23.4M 2.15%
300,000
– –
DXCM icon
17
DexCom
DXCM
$32.2B
$22.6M 2.07%
+605,056
New +$23.5M
TVTX icon
18
Travere Therapeutics
TVTX
$5.2B
$20.2M 1.85%
1,740,000
+736,400
+73% +$12.2M
TCDA
19
DELISTED
Tricida, Inc. Common Stock
TCDA
$18.1M 1.66%
586,929
-837,069
-59% -$28M
DERM
20
DELISTED
Dermira, Inc.
DERM
$16.8M 1.54%
2,621,333
+1,068,433
+69% +$8.92M
PRTA icon
21
Prothena Corp
PRTA
$425M
$16.2M 1.49%
2,066,041
+389,791
+23% +$3.46M
IONS icon
22
Ionis Pharmaceuticals
IONS
$8.6B
$16.2M 1.49%
+270,000
New +$17.6M
TNDM icon
23
Tandem Diabetes Care
TNDM
$1.34B
$14.7M 1.35%
+250,000
New +$16M
MRTX
24
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.6M 1.25%
175,000
– –
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$13M 1.19%
1,000,000
+657,936
+192% +$7.94M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Great Point Partners held 48 positions worth $1.09B, up 21% from $901M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Great Point Partners deployed $375M of net new capital in Q3 2019, opening 18 new positions and adding to 11 existing holdings. Its largest new stake was Nektar Therapeutics: 141,667 shares worth $38.7M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 90% a quarter earlier.

On the sell side, the largest reduction was Tricida, Inc. Common Stock, an estimated $28M trimmed.

  • Great Point Partners's largest Q3 2019 buy was Nektar Therapeutics: 141,667 shares worth $38.7M.
  • Great Point Partners added most to Zymeworks in Q3 2019, an estimated $35.1M increase.
  • Great Point Partners's biggest Q3 2019 reduction was Tricida, Inc. Common Stock, cutting an estimated $28M.
  • Great Point Partners fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019, selling an estimated $15.3M.
  • Great Point Partners's ten largest holdings make up 60% of its $1.09B portfolio in Q3 2019.
  • Great Point Partners opened 18 new positions and closed 7 in Q3 2019.
  • Great Point Partners's portfolio value rose 21% quarter-over-quarter to $1.09B.

Based on Great Point Partners's 13F filing for Q3 2019, filed 15 Nov 2019.